-
公开(公告)号：EP3835321A1
公开(公告)日：2021-06-16
申请号：EP19847615.2
申请日：2019-08-09
发明人： IGAWA, Tomoyuki , SAKURAI, Mika , SHIMIZU, Shun , HORI, Yuji , HIRONIWA, Naoka , SAVORY, Nasa , NARITA, Yoshinori , KAMIKAWA, Takayuki , MIYAZAKI, Taro , KADONO, Shojiro , HASEGAWA, Masami , TATSUMI, Kanako , HAYASAKA, Akira , KAWAI, Takeaki , MIMOTO, Futa , KAWAUCHI, Hiroki , KAMIMURA, Masaki
IPC分类号： C07K16/28 , A61K39/395 , A61K47/64 , A61K47/68 , A61P35/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/13 , C12N15/63 , C12P21/08
摘要： An objective of the present disclosure is to provide anti-CD137 antigen-binding molecules which have immunocyte-activating effect, cytotoxic activity, or anti-tumor activity, and meanwhile have reduced effect on non-tumor tissues such as normal tissues and produce less side effects, and methods of using the same.
Anti-CD137 antigen-binding molecules which have immunocyte-activating effect, cytotoxic activity, or anti-tumor activity, and meanwhile have reduced effect on non-tumor tissues such as normal tissues and produce less side effects, are provided by discovering and producing CD137 antigen-binding molecules whose binding activity to CD137 depends on various substances (for example, small molecule compounds) in target tissues. Methods of using the same, pharmaceutical formulations, and such are also provided.
The present disclosure also provides an antigen-binding molecule whose binding activity to an antigen varies depending on a small molecule compound, a preparation method thereof, and uses thereof.-
公开(公告)号：EP2330193B1
公开(公告)日：2015-06-17
申请号：EP09816184.7
申请日：2009-09-25
发明人： IGAWA, Tomoyuki , ISHII, Shinya , MAEDA, Atsuhiko , SAKURAI, Mika , KOJIMA, Tetsuo , TACHIBANA, Tatsuhiko , SHIRAIWA, Hirotake , TSUNODA, Hiroyuki , HIGUCHI, Yoshinobu
IPC分类号： C12N15/09 , A61K39/395 , A61P1/04 , A61P1/16 , A61P3/10 , A61P7/06 , A61P9/00 , A61P9/10 , A61P11/00 , A61P11/06 , A61P13/12 , A61P15/08 , A61P17/00 , A61P17/06 , A61P19/02 , A61P19/10 , A61P21/00 , A61P25/00 , A61K39/00 , C07K16/28
CPC分类号： C07K16/2866 , A61K39/00 , A61K2039/505 , C07K16/461 , C07K2317/24 , C07K2317/41 , C07K2317/76 , C07K2317/92
-
公开(公告)号：EP2206775B1
公开(公告)日：2016-06-29
申请号：EP08833735.7
申请日：2008-09-26
发明人： IGAWA, Tomoyuki , SAKURAI, Mika , KOJIMA, Tetsuo , TACHIBANA, Tatsuhiko , SHIRAIWA, Hirotake , TSUNODA, Hiroyuki , MAEDA, Atsuhiko
IPC分类号： C12N15/09 , A61K39/395 , C07K16/28
CPC分类号： C07K16/2866 , A61K2039/505 , C07K2317/24 , C07K2317/53 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92 , G01N33/6854 , G01N33/6869 , G01N2333/7155 , G01N2500/04 , G01N2500/10
-
公开(公告)号：EP2330193A1
公开(公告)日：2011-06-08
申请号：EP09816184.7
申请日：2009-09-25
发明人： IGAWA, Tomoyuki , ISHII, Shinya , MAEDA, Atsuhiko , SAKURAI, Mika , KOJIMA, Tetsuo , TACHIBANA, Tatsuhiko , SHIRAIWA, Hirotake , TSUNODA, Hiroyuki , HIGUCHI, Yoshinobu
IPC分类号： C12N15/09 , A61K39/395 , A61P1/04 , A61P1/16 , A61P3/10 , A61P7/06 , A61P9/00 , A61P9/10 , A61P11/00 , A61P11/06 , A61P13/12 , A61P15/08 , A61P17/00 , A61P17/06 , A61P19/02 , A61P19/10 , A61P21/00 , A61P25/00 , A61P27/02 , A61P29/00
CPC分类号： C07K16/2866 , A61K39/00 , A61K2039/505 , C07K16/461 , C07K2317/24 , C07K2317/41 , C07K2317/76 , C07K2317/92
摘要： The present invention provides pharmaceutical compositions comprising second-generation molecules that are superior than TOCILIZUMAB, by altering the amino acid sequences of the variable and constant regions of TOCILIZUMAB, which is a humanized anti-IL-6 receptor IgG1 antibody, to enhance the antigen-neutralizing ability and increase the pharmacokinetics, so that the therapeutic effect is exerted with a less frequency of administration, and the immunogenicity, safety and physicochemical properties (stability and homogeneity) are improved. The present invention also provides methods for producing these pharmaceutical compositions.
The present inventors have successfully generated second-generation molecules that are superior to TOCILIZUMAB by appropriately combining amino acid sequence alterations in the CDR domains, variable regions, and constant regions.摘要翻译： 本发明通过改变作为人源化抗IL-6受体IgG1抗体的TOCILIZUMAB的可变区和恒定区的氨基酸序列来提供优于TOCILIZUMAB的第二代分子的药物组合物，以增强抗原 - 中和能力增强，药代动力学改善，治疗效果较差，免疫原性，安全性和物理化学性质（稳定性和均一性）均有改善。 本发明还提供了制备这些药物组合物的方法。 通过适当地组合CDR结构域，可变区和恒定区中的氨基酸序列改变，本发明人成功地生产出优于TOCILIZUMAB的第二代分子。
-
公开(公告)号：EP4104857A1
公开(公告)日：2022-12-21
申请号：EP21754475.8
申请日：2021-02-10
发明人： SAKURAI, Mika , NARITA, Yoshinori , TANIGUCHI, Kenji , MIKAMI, Hirofumi , HORIKAWA, Sayuri , UCHIKAWA, Ryo , ONO, Natsuki , HAMADA, Koki
IPC分类号： A61K39/395 , A61K45/00 , A61P35/00 , A61P43/00 , C07K16/28 , C07K16/30 , C07K16/46 , C12N15/13
摘要： An objective of the present disclosure is to provide: anticancer agents having an immune cell-activating effect, a cytotoxic activity, or an antitumor activity, but having a low effect on non-tumor tissues such as normal tissues and having few side effects; combination therapies using those anticancer agents and other anticancer agents; and pharmaceutical combinations for use in those combination therapies.
Anticancer agents expected to be applied to various types of cancers, which have an immune cell-activating effect, a cytotoxic activity, or an antitumor activity while having a low effect on non-tumor tissues such as normal tissues and having few side effects by using as an active ingredient an anti-CD 137 antigen-binding molecule of the present disclosure, the binding activity of which to CD137 changes depending on various substances (for example, low molecular weight compounds) in target tissues, are provided. Combination therapies using those anticancer agents and other anticancer agents, and pharmaceutical compositions for use in those combination therapies are also provided.-
公开(公告)号：EP3199628A1
公开(公告)日：2017-08-02
申请号：EP15844692.2
申请日：2015-09-25
发明人： NEZU, Junichi , NARITA, Atsushi , ISHIGURO, Takahiro , SAKURAI, Mika , SHIRAIWA, Hirotake , HIRONIWA, Naoka , IGAWA, Tomoyuki , KAWAI, Yumiko
IPC分类号： C12N15/09 , A61K39/395 , A61P35/00 , C07K16/28 , C07K16/46 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12P21/08
CPC分类号： C07K16/468 , A61K39/395 , A61K2039/505 , C07K16/28 , C07K16/2809 , C07K16/30 , C07K16/303 , C07K16/46 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2317/524 , C07K2317/526 , C07K2317/565 , C07K2317/567 , C07K2317/71 , C07K2317/73 , C07K2317/92 , C07K2317/94 , C12N5/10 , C12N15/09
摘要： Novel multispecific antigen-binding molecules maintaining excellent cellular cytotoxicity and high stability, which comprise a domain that contains an antibody variable region having glypican 3-binding activity and a domain that contains an antibody variable region having T-cell receptor complex-binding activity, were discovered. Since the molecules of the present invention show a strong cytotoxicity against cells and tissues expressing glypican 3, it is possible to produce novel pharmaceutical compositions for treating or preventing various cancers.
摘要翻译： 包含含有具有磷脂酰肌醇蛋白聚糖3结合活性的抗体可变区和含有具有T细胞受体复合体结合活性的抗体可变区的结构域的结构域的，保持优异的细胞毒性和高稳定性的新型多特异性抗原结合分子为 发现。 由于本发明的分子对表达磷脂酰肌醇蛋白聚糖3的细胞和组织显示出强烈的细胞毒性，因此可以生产用于治疗或预防各种癌症的新药物组合物。
-
公开(公告)号：EP4461751A2
公开(公告)日：2024-11-13
申请号：EP24187720.8
申请日：2014-11-11
IPC分类号： C07K16/42
摘要： The present inventors have successfully prepared an antigen-binding molecule comprising an antibody variable region that has binding activity against a molecule expressed on the surface of a T cell and a molecule expressed on the surface of any other immunocyte, but does not bind to these molecules at the same time. The present invention allows the preparation of an antigen-binding molecule capable of circumventing adverse reactions that may be caused by the cross-linking of T cells to other immunocytes, and provides an antigen-binding molecule suitable as a drug.
-
公开(公告)号：EP4197545A1
公开(公告)日：2023-06-21
申请号：EP21850145.0
申请日：2021-07-30
发明人： IGAWA, Tomoyuki , SAKURAI, Mika , SUZUKI, Takashi , TATSUMI, Kanako , SHIMIZU, Shun , TAMADA, Koji , SAKODA, Yukimi
IPC分类号： A61K35/12 , A61K39/395 , A61P35/00 , A61P43/00 , C07K14/705 , C07K19/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/12 , C12N15/62 , C12N15/63
摘要： The present invention provides a pharmaceutical composition comprising cells expressing a chimeric receptor, for use in combination with administration of an antigen-binding molecule, wherein the chimeric receptor comprises an extracellular domain, the extracellular domain comprises an extracellular domain of an immunoreceptor, an extracellular domain variant of an immunoreceptor, or a portion thereof, and the antigen-binding molecule is a multispecific antigen-binding molecule having a target antigen recognition site and an immunoreceptor recognition site which recognizes the immunoreceptor.
-
公开(公告)号：EP4023230A1
公开(公告)日：2022-07-06
申请号：EP20819246.8
申请日：2020-06-05
摘要： The present disclosure provides a pharmaceutical composition comprising an antibody having ADCC activity, a T cell-redirecting antibody, or a cell expressing a chimeric receptor, for use in combination with the administration of an antigen binding molecule capable of binding to a target antigen, wherein the primary molecule comprises a linker that is cleaved by protease, the antigen binding molecule obtained through the cleavage of the linker has the ability to bind to the target antigen, variable regions of the antibody having ADCC activity or the T cell-redirecting antibody, and an extracellular binding domain of the chimeric receptor bind to a cell expressing the target antigen via binding to the antigen binding molecule resulting from the cleavage of the cleavable linker.
-
公开(公告)号：EP3957325A1
公开(公告)日：2022-02-23
申请号：EP20791023.3
申请日：2020-04-17
发明人： SAKURAI, Mika , IGAWA, Tomoyuki , TAMADA, Koji , SAKODA, Yukimi
IPC分类号： A61K39/395 , A61P35/00 , C12N5/10 , C12N1/15 , C12N1/19 , C12N1/21 , C12N15/13 , C12N15/62 , C12N15/63 , A61K38/16 , A61K35/17
摘要： The present disclosure provides a pharmaceutical composition for use in combination with administration of a mutated antibody having a mutation, including substitution, deletion, addition or modification, of at least one amino acid in a CH1 region, a CH2 region, a CH3 region, a CL region, or a framework region, wherein the pharmaceutical composition comprises a cell expressing a chimeric receptor, the mutated antibody is capable of binding to the extracellular binding domain of the chimeric receptor via a moiety having the mutation, and the extracellular binding domain does not bind to an antibody free of the mutation.
-
-
-
-
-
-
-
-
-
搜索结果
15 条记录 (耗时 0.019 秒)
